A carregar...
Acquired amegakaryocytic thrombocytopenia after durvalumab administration
Immune checkpoint inhibitors (ICIs), despite their ability to potentiate antitumor T-cell responses, may cause various immune-related adverse events. Most cases of thrombocytopenia induced by ICIs have revealed a pathophysiologic mechanism of immune thrombocytopenia with increased platelet destructi...
Na minha lista:
| Publicado no: | J Clin Exp Hematop |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
JSLRT
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8053569/ https://ncbi.nlm.nih.gov/pubmed/33431742 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3960/jslrt.20047 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|